FENNEC PHARMACEUTICALS INC. 8-K

What Happened
Fennec Pharmaceuticals, Inc. (FENC) announced on April 7, 2026 (via an 8-K and accompanying press release) that the University of Arizona Cancer Center has initiated an investigator‑sponsored study to evaluate PEDMARK® (sodium thiosulfate injection). The study will evaluate PEDMARK in adolescent, young adult and adult patients with head and neck and testicular cancers who are receiving cisplatin chemotherapy.

Key Details

• Filing: Current Report on Form 8-K furnished April 7, 2026; press release included as Exhibit 99.1.
• Sponsor/site: Investigator‑sponsored by the University of Arizona Cancer Center.
• Population & indication: Adolescents, young adults and adults with head & neck and testicular cancers receiving cisplatin.
• Drug: PEDMARK® (sodium thiosulfate injection); study evaluates its use in patients undergoing cisplatin therapy.

Why It Matters
This filing notifies investors that an independent research team has begun a clinical evaluation of PEDMARK in additional cancer populations and age groups beyond prior studies. While the 8-K does not report results or change commercial or financial guidance, the study could generate clinical data that stakeholders may monitor for future regulatory, clinical or commercial implications. Investors should watch for future updates or results from the investigator‑sponsored study.